Recursion Pharmaceuticals (RXRX)
(Delayed Data from NSDQ)
$6.80 USD
-0.14 (-2.02%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $6.78 -0.02 (-0.29%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
RXRX 6.80 -0.14(-2.02%)
Will RXRX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for RXRX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RXRX
Recursion Stock Down Despite Meeting Goal in Brain Disease Study
Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Tops Revenue Estimates
RXRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Theravance Biopharma (TBPH) Reports Q2 Loss, Lags Revenue Estimates
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
Other News for RXRX
Insider Sale: Director Blake Borgeson Sells Shares of Recursion Pharmaceuticals Inc (RXRX)
IN BRIEF: Angle celebrates agreement with Recursion Pharmaceuticals
Looking Into Recursion Pharmaceuticals's Recent Short Interest
AI-Focused Drug Discovery Stocks +6% Last Week Vs. -8% Previous Week
Recursion: AI Is Only As Good As The Data